| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/SYN.1075 |
| P698 | PubMed publication ID | 11391780 |
| P2093 | author name string | J A Ramos | |
| J Fernández-Ruiz | |||
| A Sánchez | |||
| F Berrendero | |||
| C Puerta | |||
| A García-Merino | |||
| A Cabranes | |||
| P2860 | cites work | Cannabinoids control spasticity and tremor in a multiple sclerosis model | Q28138564 |
| 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain | Q28290395 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Isolation and structure of a brain constituent that binds to the cannabinoid receptor | Q29547476 | ||
| Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development | Q31522100 | ||
| Presence and functional regulation of cannabinoid receptors in immune cells | Q33720122 | ||
| The endogenous cannabinoid system and brain development | Q33815201 | ||
| The endocannabinoid system as a target for therapeutic drugs. | Q33934278 | ||
| Drug treatment of multiple sclerosis | Q34007633 | ||
| Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor | Q34358410 | ||
| Functional role of high-affinity anandamide transport, as revealed by selective inhibition | Q34436019 | ||
| Pharmacology of cannabinoid CB1 and CB2 receptors. | Q34442847 | ||
| Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Tetrahydrocannabinol for tremor in multiple sclerosis | Q34708416 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| Pharmacology of cannabinoid receptors | Q40437020 | ||
| Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis | Q40437100 | ||
| The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. | Q42450193 | ||
| Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 | ||
| Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis | Q44929830 | ||
| Cardiovascular actions of cannabinoids and their generation during shock | Q45115193 | ||
| The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease | Q45300428 | ||
| Type IV phosphodiesterase inhibition in experimental allergic encephalomyelitis of Lewis rats: sequential gene expression analysis of cytokines, adhesion molecules and the inducible nitric oxide synthase | Q46716536 | ||
| Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action | Q48309971 | ||
| Atypical location of cannabinoid receptors in white matter areas during rat brain development | Q48679760 | ||
| Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers | Q49149336 | ||
| Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. | Q54001516 | ||
| Nabilone in the treatment of multiple sclerosis. | Q55065083 | ||
| P433 | issue | 3 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| striatum | Q1319792 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 195-202 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Synapse | Q7662025 |
| P1476 | title | Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis | |
| P478 | volume | 41 |
| Q92912268 | A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis |
| Q44830885 | A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'. |
| Q35166600 | Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases |
| Q36157657 | Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? |
| Q34786839 | Cannabinoids and multiple sclerosis |
| Q81478365 | Cannabinoids and multiple sclerosis |
| Q35046205 | Cannabinoids and neuroinflammation |
| Q37960199 | Cannabinoids, multiple sclerosis and neuroprotection |
| Q56334625 | Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination |
| Q28267822 | Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis |
| Q35028750 | Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS |
| Q34912871 | Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 |
| Q48895143 | Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist |
| Q36319914 | Mechanism of experimental autoimmune encephalomyelitis in Lewis rats: recent insights from macrophages |
| Q34597217 | Multiple sclerosis may disrupt endocannabinoid brain protection mechanism |
| Q33715420 | New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids |
| Q36941905 | Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances |
| Q24643876 | The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin |
| Q35876026 | The endocannabinoid system and its therapeutic exploitation |
| Q34098196 | The endocannabinoid system as a target for the treatment of neurodegenerative disease |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q36150541 | The safety of cannabinoids for the treatment of multiple sclerosis |
| Q36341688 | The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids |
| Q45047941 | Therapeutic action of cannabinoids in a murine model of multiple sclerosis. |
Search more.